Pearl River Capital’s TherapeuticsMD TXMD Stock Holding History

Pearl River Capital’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-85	Closed	-$16K	–	780
2018 Q4	$16K	Buy	+85	New	+$20.7K	0.07%	385

Other funds holding TXMD

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Pearl River Capital's TXMD Position: Q1 2019 in Review

Pearl River Capital sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 85 shares — an estimated $16K sold.

Pearl River Capital first reported a position in TXMD in Q4 2018 and held it in 1 quarter. The position peaked at $16K in Q4 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

Pearl River Capital reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 85 TherapeuticsMD shares in Q1 2019, an estimated $16K.
Pearl River Capital first reported a position in TherapeuticsMD in Q4 2018 and held it in 1 quarter.
Pearl River Capital's TherapeuticsMD position peaked at $16K in Q4 2018.
146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.